News

Shares of Axsome Therapeutics (NASDAQ: AXSM) were sinking 6.8% lower as of 11:19 a.m. ET on Tuesday. The decline came after Culper Research announced a short position in the biotech stock before the market open.

Culper alleged that Axsome's commercialization of depression drug Auvelity "has been aided by undisclosed consignment deals with dodgy mail-order pharmacies that subvert prior authorizations." It also claimed that these deals are "inflating script counts and reported revenues."

How concerning are the allegations about Axsome?

Culper Research said that its report and corresponding short position in Axsome was based on interviews with former company sales representatives, pharmacies, prescribing physicians, and patients. The short-seller also stated that it obtained a prescription for Auvelity through Axsome's telehealth partner without providing any documentation of failure with other depression drugs -- an important requirement for the insurer it used.

A key concern about Culper's allegations is that some part of Axsome's recorded revenue might never be received. If pharmacies are filling prescriptions for Auvelity without obtaining prior authorizations, insurers won't pay for the drug. Culper noted that Axsome's receivables have jumped more than $81 million to $101.4 million since Auvelity was launched in October 2022.

If Culper's allegations prove to be correct, Axsome could have to restate its revenue at some point and write down its accounts receivables. This would almost certainly cause the stock to fall significantly.

What should investors do?

Axsome Therapeutics had not publicly responded to Culper Research's allegations at the time of this writing. Investors who own the stock will probably want to wait to hear the company's side of the story before making any decisions. Anyone who is considering buying Axsome shares will also likely be better off staying on the sidelines until there's more clarity.

Should you invest $1,000 in Axsome Therapeutics right now?

Before you buy stock in Axsome Therapeutics, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Axsome Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $746,217!*

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.

See the 10 stocks »

*Stock Advisor returns as of June 10, 2024

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Axsome Therapeutics. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.